CD8A and melanoma: Moreover, adoptive cell therapy shows that CD8+ T cells that produce IL-9 (Tc9 cells) tend to have better persistence and antitumor responses against a B16 melanoma model than type 1 cytotoxic CD8+ T cells (Tc1 cells) [81].